111797-22-9

Basic information

• Product Name: MD2-IN-1
• Synonyms: MD2-IN-1
• CAS NO: 111797-22-9
• Molecular Formula: C₂₀H₂₂O₆
• Molecular Weight: 358.39
• Mol File: 111797-22-9.mol
• Article Data: 15

Chemical Properties

• Melting Point: 131-132 °C
• Boiling Point: 521.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.156±0.06 g/cm3(Predicted)
• CAS DataBase Reference: MD2-IN-1(CAS DataBase Reference)
• NIST Chemistry Reference: MD2-IN-1(111797-22-9)
• EPA Substance Registry System: MD2-IN-1(111797-22-9)

Safety Data

• Hazardous Substances Data: 111797-22-9(Hazardous Substances Data)

Usage

General Description

MD2-IN-1 is a chemical compound that acts as a potent inhibitor of MyD88 dimerization and TLR4 signaling, making it a promising therapeutic agent for treating inflammatory diseases and sepsis. By disrupting the interaction between MyD88 and TLR4, MD2-IN-1 can effectively suppress the activation of the NF-κB and MAPK pathways, leading to reduced production of pro-inflammatory cytokines and mitigating the inflammatory response. Additionally, MD2-IN-1 has been shown to improve survival rates in mouse models of endotoxemia and sepsis, suggesting its potential for clinical applications in managing immune-related disorders. Furthermore, its ability to target specific components of the innate immune system makes MD2-IN-1 a valuable tool for studying the underlying mechanisms of inflammation and identifying novel therapeutic strategies.

Upstream product

• 93-15-2 1,2-dimethoxy-4-(2-propenyl)benzene 
• 182163-96-8 3,4,5-trimethoxyphenylboronic Acid 
• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 

Downstream Products

• 881382-89-4 C₂₀H₂₂O₆ 
• 110148-25-9 3-(3,4,5-trimethoxyphenyl)-1-(3,4-dimethoxyphenyl)propan-1-one 
• 1215204-90-2 1,2-dimethoxy-4-(3-(3,4,5-trimethoxyphenyl)prop-1-enyl)benzene 
• 1334727-47-7 6-(3,4-dimethoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-1-phenyl-3,4-dihydropyrimidine-2(1H)-thione 
• 1334727-45-5 6-(3,4-dimethoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-3,4-dihydropyrimidin-2(1H)-one 
• 1334727-43-3 3-(3,4-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole 
• 219698-37-0 C₂₆H₂₈N₂O₅ 
• 1334727-46-6 6-(3,4-dimethoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-1-methyl-3,4-dihydropyrimidine-2(1H)-thione 
• 219698-41-6 C₂₂H₂₆N₂O₆ 
• 219698-40-5 C₂₁H₂₄N₂O₆ 
• 1334727-58-0 C₃₂H₃₂N₂O₈S 
• 1334727-57-9 C₃₁H₃₀N₂O₇S 
• 1334727-56-8 [4-(3,4-dimethoxyphenyl)-6-(3,4,5-trimethoxyphenyl)pyrimidin-2-yl]hydrazine 
• 102472-46-8 6-[3-(3,4-dimethoxy-phenyl)-propyl]-2,3,4-trimethoxy-benzaldehyde 

Relevant articles and documents

A new chalcone derivative with promising antiproliferative and anti-invasion activities in glioblastoma cells

Glioblastoma (GBM) is the most common and most deadly primary malignant brain tumor. Current therapies are not effective, the average survival of GBM patients after diagnosis being limited to few months. Therefore, the discovery of new treatments for this highly aggressive brain cancer is urgently needed. Chalcones are synthetic and naturally occurring compounds that have been widely investigated as anticancer agents. In this work, three chalcone derivatives were tested regarding their inhibitory activity and selectivity towards GBM cell lines (human and mouse) and a non-cancerous mouse brain cell line. The chalcone 1 showed the most potent and selective cytotoxic effects in the GBM cell lines, being further investigated regarding its ability to reduce critical hallmark features of GBM and to induce apoptosis and cell cycle arrest. This derivative showed to successfully reduce the invasion and proliferation capacity of tumor cells, both key targets for cancer treatment. Moreover, to overcome potential systemic side effects and its poor water solubility, this compound was encapsulated into liposomes. Therapeutic concentrations were incorporated retaining the potent in vitro growth inhibitory effect of the selected compound. In conclusion, our results demonstrated that this new formulation can be a promising starting point for the discovery of new and more effective drug treatments for GBM.

Design, synthesis, characterization and in silico molecular docking studies and in vivo anti-inflammatory activity of pyrazoline clubbed thiazolinone derivatives

The pyrazolines give the reactions of aliphatic derivatives, resembling unsaturated compounds in their behavior towards permanganate and nascent hydrogen. This nucleus has been associated with various biological activities, including inflammatory action.

A class of novel tubulin polymerization inhibitors exert effective anti-tumor activity via mitotic catastrophe

In current work, a class of novel 4,5-dihydro-1H-pyrazole-1-carboxylate derivatives (E01-E28) were designed, synthesized and evaluated. Among them, the most potent compound E24 exhibited comparable activity against a panel of cancer cells (GI50